Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Danaher Corporation has demonstrated a strong performance in its life sciences and diagnostics sectors, with performance obligations increasing to $4.9 billion in the second quarter of 2025, reflecting robust demand. The company is also anticipating a growth ramp in the life sciences segment, projecting approximately 4.5% growth in the fourth quarter, supported by favorable market conditions and new product launches. Additionally, the respiratory segment appears well-positioned with expected revenues of $300-350 million in the third quarter and $450-500 million in the fourth quarter of 2025, indicating a resilient performance despite potential headwinds in other areas.

Bears say

Danaher is experiencing a decline in expected revenue recognition, with only 46% of 2Q25 obligations anticipated to convert into revenue within the next year, a decrease from 48% in the previous quarter. The company faces significant risks from geopolitical disruptions, foreign exchange fluctuations, and uncertainty regarding the recovery of high-growth end-markets, particularly in China. Additionally, the guidance for Biotechnology and Life Sciences revenue has fallen short of expectations for 3Q25, indicating potential challenges in sustaining growth moving forward.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $251.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $251.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.